Biopharmx Corp (NYSE:BPMX) was the recipient of a significant drop in short interest during the month of June. As of June 30th, there was short interest totalling 5,319,631 shares, a drop of 1.7% from the June 15th total of 5,411,971 shares. Currently, 10.2% of the shares of the company are sold short. Based on an average trading volume of 776,056 shares, the short-interest ratio is currently 6.9 days.

Biopharmx Corp (NYSE:BPMX) opened at 0.459 on Friday. The firm has a 50-day moving average of $0.51 and a 200-day moving average of $0.51. Biopharmx Corp has a one year low of $0.19 and a one year high of $1.22. The company’s market cap is $34.03 million.

Separately, ValuEngine raised shares of Biopharmx Corp from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 24th.

COPYRIGHT VIOLATION NOTICE: “Biopharmx Corp (NYSE:BPMX) Sees Significant Decline in Short Interest” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with's FREE daily email newsletter.